NCT05601271View on ClinicalTrials.gov

Effect of Allopurinol on Markers of Mineral and Bone Metabolism

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2025

Conditions
Chronic Kidney DiseasesOsteodystrophyUric Acid Concentration, Serum, Quantitative Trait Locus 7
Interventions
DRUG

Allopurinol

Allopurinol 100 to 300 mg a day for 3 months

Trial Locations (1)

05403000

Hospital das Clinicas HCFMUSP, São Paulo

All Listed Sponsors
lead

University of Sao Paulo General Hospital

OTHER

NCT05601271 - Effect of Allopurinol on Markers of Mineral and Bone Metabolism | Biotech Hunter | Biotech Hunter